34 related articles for article (PubMed ID: 1675150)
1. [EGF binding site number of rat anterior pituitary is increased by chronic administration with dopaminergic agonist, CV 205-502].
Birman P; Bai-Grenier F; Joubert D
C R Acad Sci III; 1991; 312(6):241-5. PubMed ID: 1675150
[TBL] [Abstract][Full Text] [Related]
2. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
3. [Effects of growth factors and estrogen on the proliferation and prolactin gene expression in anterior pituitary cells of rats].
Wu X; Zhang R; Di A; Shan H; Xu R
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Oct; 21(5):331-7. PubMed ID: 12567429
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor and prolactin in rat anterior pituitary after chronic treatment with estradiol and triiodothyronine.
Nedvídková J; Schreiber V
Endocr Regul; 1993 Jun; 27(2):71-4. PubMed ID: 8003713
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor: a potential paracrine and autocrine system within the pituitary.
Mouihate A; Lestage J
Neuroreport; 1995 Jul; 6(10):1401-4. PubMed ID: 7488734
[TBL] [Abstract][Full Text] [Related]
6. [The effect of lithium treatment on the activity of central dopaminergic neurons].
Koyama T
Hokkaido Igaku Zasshi; 1987 May; 62(3):402-16. PubMed ID: 3111963
[TBL] [Abstract][Full Text] [Related]
7. The effects of epidermal growth factor on cell proliferation and prolactin production by GH3 rat pituitary cells.
Yajima Y; Saito T
J Cell Physiol; 1984 Aug; 120(2):249-56. PubMed ID: 6086677
[TBL] [Abstract][Full Text] [Related]
8. The stimulated C-kinase activity in estradiol-treated rat pituitaries is reduced by chronic treatment with the dopamine agonist CV 205-502.
Birman P; Touraine P; Bai-Grenier F; Dubray C; Kaabache T; Peillon F; Joubert D
Acta Endocrinol (Copenh); 1989 Oct; 121(4):489-94. PubMed ID: 2572127
[TBL] [Abstract][Full Text] [Related]
9. Modifications of the high and low affinity pituitary domperidone-binding sites in chronic estrogenized rats.
Bression D; Brandi AM; Le Dafniet M; Cesselin F; Hamon M; Martinet M; Kerdelhue B; Peillon F
Endocrinology; 1983 Nov; 113(5):1799-805. PubMed ID: 6628328
[TBL] [Abstract][Full Text] [Related]
10. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor induces an increase in cell adhesion and an arrangement of actin skeleton in stress fibres in pituitary cultured cells from infantile rats but not adult rats.
Toral C; Solano-Agama MC; Luna J; Romano MC; Mendoza-Garrido ME
J Cell Physiol; 2003 Apr; 195(1):80-91. PubMed ID: 12599211
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Enjalbert A; Bockaert J
Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
[TBL] [Abstract][Full Text] [Related]
13. Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurones in vitro and in vivo.
Hanke M; Farkas LM; Jakob M; Ries R; Pohl J; Sullivan AM
Neuroscience; 2004; 124(4):757-66. PubMed ID: 15026116
[TBL] [Abstract][Full Text] [Related]
14. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
15. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
Tresguerres JA; Esquifino AI
Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
[TBL] [Abstract][Full Text] [Related]
16. Suppression of prolactin release and mRNA accumulation by two novel dopamine agonist agents.
Davis JR; Vidal ME; Wilson EM; Sheppard MC
Acta Endocrinol (Copenh); 1989 May; 120(5):672-6. PubMed ID: 2567101
[TBL] [Abstract][Full Text] [Related]
17. Distribution of epidermal growth factor binding sites in the adult rat anterior pituitary gland.
Chabot JG; Walker P; Pelletier G
Peptides; 1986; 7(1):45-50. PubMed ID: 3012489
[TBL] [Abstract][Full Text] [Related]
18. Estrogen increases the release of epidermal growth factor from individual pituitary cells in female rats.
Mouihate A; Lestage J
J Endocrinol; 1995 Sep; 146(3):495-500. PubMed ID: 7595145
[TBL] [Abstract][Full Text] [Related]
19. Lactation inhibition by the dopamine agonist CV 205-502.
van der Heijden PF; Kremer JA; Brownell J; Rolland R
Br J Obstet Gynaecol; 1991 Mar; 98(3):270-6. PubMed ID: 1673628
[TBL] [Abstract][Full Text] [Related]
20. Dopamine reuptake inhibitors and dopamine releasers: differential effect on plasma prolactin in the rat.
Cella S; Apud J; Racagni G; Müller EE
Pharmacol Res Commun; 1982 Oct; 14(9):839-49. PubMed ID: 7178213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
